Aix-Marseille Université
RHU Project Manager
Administration of the consortium, management of the RHU
(scientific-regulatory-budgetary aspects, human resources),
communication and dissemination in connection with
the consortium and ATCG-Partners
Aix-Marseille Université, AP-HM
Investigational clinical center of Marseille
Principal investigator-study coordinator of
the early phase randomized umbrella clinical trial
Aix-Marseille Université, AP-HM
Investigational clinical center of Marseille (and satellite centers)
Principal investigator-study coordinator of the biomarkers protocol
Hôpitaux de Toulouse-Université Paul Sabatier
Investigational clinical center of the Toulouse University Hospital (and satellite centers)
Co-principal investigator of the biomarkers protocol and
of the early phase randomized umbrella clinical trial
Centre Léon Bérard (CLB)
Investigational clinical center of the CLB Lyon (and satellite centers)
Co-principal investigator of the biomarkers protocol and of
the early phase randomized umbrella clinical trial
AstraZeneca
Medical Director Oncology France
Link between AZ teams in the US & the UK, and the AP-HM
and RHU coordination teams (supply, regulatory and legal aspects of experimental molecules)
Centre Léon Bérard (CLB)
Clinical Research and Innovation Department
Study design and statistical analysis of the
early phase randomized umbrella clinical trial
Aix Marseille Université AP-HM
Vasculo-monitoring platform of APHM
Study of the link between immunotherapy and
the endothelial compartment in PIONeeR patients
Aix-Marseille Université, APHM
Centre de Recherche en Cancérologie de Marseille (CRCM)- SMARTc laboratory
Clinical pharmacokinetics and toxicology department
PK-PD study and modeling
Aix-Marseille Université- SMARTc laboratory (CRCM)
Engineer
Mathematical modeling of the efficacy-toxicity balance
of anti-PD (L)1 based on PK-PD studies in PIONeeR patients
Inria – Inserm team COMPO (CRCM)
Biostatistician
Biostatistical, integrative (machine learning)
and mechanistic analyses of the PIONeeR BioMarkers protocol and
mathematical modeling of the response to immunotherapies
